Epirubicin plus paclitaxel regimen as second-line treatment of patients with small-cell lung cancer

Giulia Pasello, Paolo Carli, Fabio Canova, Laura Bonanno, Valentina Polo, Giulia Zago, Loredana Urso, Pierfranco Conte, Adolfo Favaretto

Research output: Contribution to journalArticle


Background/Aim: Most patients with small cell lung cancer (SCLC) experience relapse within one year after first-line treatment. The aim of this study was to describe activity and safety of second-line with epirubicin at 70 mg/m2 followed by paclitaxel at 135 mg/m2 on day 1 every three weeks for a maximum of six cycles. Patients and Methods: This is a retrospective review of all patients with SCLC evaluated for second-line treatment between 2003 and 2013 at our Institution. Results: Sixty-eight patients received the study regimen of epirubicin with paclitaxel. We observed partial response in 19 (30%), stable disease in 22 (34%) and total early failure rate in 23 (36%) patients. Median progression free and overall survival were 21.8 and 26.5 weeks, respectively. Haematological toxicities were as follows: grade 3-4 leukopenia and neutropenia in 18 (31%) and 30 (22%) of patients, respectively; grade 3 anaemia and grade 4 thrombocytopenia were reported in 2 (3%) and 5 (9%) of patients, respectively. Conclusion: Epirubicin with paclitaxel is an active and tolerable second-line regimen in patients with SCLC.

Original languageEnglish
Pages (from-to)2183-2189
Number of pages7
JournalAnticancer Research
Issue number4
Publication statusPublished - Apr 1 2015


  • Chemotherapy
  • Epirubicin
  • Paclitaxel
  • Recurrence
  • Small cell carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Epirubicin plus paclitaxel regimen as second-line treatment of patients with small-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this